The present disclosure describes solid compositions comprising a paraffin inhibitor and a corrosion inhibitor. The paraffin inhibitors include polymers having various repeat units containing one or more ester moieties. The corrosion inhibitors can be imidazoline compounds, quaternary ammonium compounds, or a combination thereof. These solid compositions can be used to treat subterranean hydrocarbon-containing reservoir and can inhibit or reduce paraffin deposition in the reservoir and/or inhibit or reduce corrosion in a piece of equipment in contact with the reservoir.

The present disclosure describes solid compositions comprising a paraffin inhibitor and a corrosion inhibitor. The paraffin inhibitors include polymers having various repeat units containing one or more ester moieties. The corrosion inhibitors can be imidazoline compounds, quaternary ammonium compounds, or a combination thereof. These solid compositions can be used to treat subterranean hydrocarbon-containing reservoir and can inhibit or reduce paraffin deposition in the reservoir and/or inhibit or reduce corrosion in a piece of equipment in contact with the reservoir.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

The invention relates to the field of antimicrobial materials, in particular to implantable and other medical devices, exhibiting antimicrobial activity. Provided is a method for providing a substrate with an antimicrobial coating comprising providing a substrate that is coated with a polyamine-functionalized polymer, and contacting said polyamine-functionalized polymer with an aqueous salt solution comprising at least one salt having a polarizability α.sub.37 at least 4 Å.sup.3 determined at 37° C. The salt solution may comprise one or more of NaI, KI, NaBr, KBr, NaClO.sub.4, KClO.sub.4, Na.sub.2SO.sub.4, K.sub.2SO.sub.4, Na.sub.3PO.sub.4, K.sub.3PO.sub.4, Mg(NO.sub.3).sub.2, Ca(NO.sub.3).sub.2, (NH.sub.4).sub.2SO.sub.4, NH.sub.4NO.sub.3, MgSO.sub.4, CaSO.sub.4, and Al(NO.sub.3).sub.3.

The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): ##STR00001##
comprising treating a compound of Formula (I): ##STR00002##
with a transition metal catalyst and under alkylation conditions as valence and stability permit.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

This invention relates to 4-substituted isoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.

This invention relates to 4-substituted isoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.